A notable clinical finding for the patients with the E35K and Y134S mutation is the absence of hypercalcemia or any other biochemical change that would be expected to arise with an excess of PTH-mediated signaling, which lends support to the notion that the mutations each have a biased effect on responsiveness to PTHrP versus PTH. This evidence concerns the gene PTHLH and hypercalcemia disease.